PSMD9

Across TCGA pan-cancer cohorts, PSMD9 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of PSMD9’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where PSMD9 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PSMD9 is over-expressed in tumor.

HNSC, LIHC, and KIRC are the cancer types where PSMD9 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PSMD9 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+0.767	<.001	12	view →
LIHC	Male	III,IV	+0.981	<.001	9	view →
KIRC	All	IV	+0.325	<.001	8	view →
LUSC	All	II,III,IV	+0.445	<.001	6	view →
STAD	All	II,III,IV	+0.370	<.001	6	view →
BLCA	All	All	+0.297	.005	6	view →
COAD	Female	All	+0.362	<.001	4	view →
BRCA	All	All	+0.163	.003	4	view →
CHOL	All	All	+1.454	<.001	3	view →
LUAD	Male	All	+0.242	.015	2	view →
ESCA	All	All	+0.526	.016	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

PSMD9–HNSC

Open the HNSC breakdown →